Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune’s Palforzia, expanding its broader spectrum of solutions … Continue reading Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK’s COVID-19 monoclonal antibody therapy; AstraZeneca’s Farxiga scores goal in Phase III CDK trial